The authors suggest the possibility to consider recurrent PCDH17 hypermethylation as a diagnostic and prognostic biomarker in LSCC, even if further studies enrolling more patients with different tumor grades and stages are needed [140]. This evidence concerns the gene PCDH17 and neoplasm.